Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 10/20 | 0.72 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.72 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.72 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.72 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.68 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.61 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.61 |
| ▸ | CDK2 | P24941 | 1/20 | 0.61 |
| ▸ | CDK9 | P50750 | 1/20 | 0.61 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.59 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15833785 | 0.91 | KIT (0.81) | KITDYRK1ACCNT1CCNA2CDK2 | |
| SCHEMBL13745948 | 0.86 | AXL (0.76) | KITDYRK1A | |
| SCHEMBL3351151 | 0.85 | MAPK8 (0.57) | KITMAPK8MAPK9MAPK10DYRK1A | |
| SCHEMBL8313439 | 0.85 | KIT (0.83) | KITDYRK1AMAP3K11PIK3CA | |
| SCHEMBL8941722 | 0.85 | KIT (0.74) | KITDYRK1ACCNT1CCNA2CDK2 | |
| SCHEMBL14049065 | 0.84 | DYRK1A (0.79) | MAPK8MAPK9MAPK10DYRK1A | |
| SCHEMBL8313435 | 0.84 | MAPK8 (0.71) | KITMAPK8MAPK9MAPK10DYRK1A | |
| SCHEMBL12829496 | 0.84 | MAPK8 (0.64) | KITMAPK8MAPK9MAPK10DYRK1A | |
| SCHEMBL4406366 | 0.84 | MAPK8 (1.00) | KITMAPK8MAPK9MAPK10DYRK1A | |
| SCHEMBL17211634 | 0.82 | KIT (0.69) | KITDYRK1ACCNT1CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2295433-A2 | JNK inhibitors | Eisai R&D Management Co., Ltd. (JP) | 2011-03-16 | — | — | EP | disclosed |
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| WO-2004078756-A2 | JNK INHIBITORS | EISAI CO., LTD. (JP) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | MAPKAPK2, MAPK1, MAPKAPK3 | KIT 3148/4885MAPK8 50/4885MAPK9 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.